Therapeutic agents for attention deficit disorders

Bibliography

• Diagnostic and Statistical Manual of Mental Disorders(DSM-III) (3rd edition). American Psychiatric Assoc., Washington DC 20005, USA (1980):41–45.
   Google Scholar
• GOLDMAN LS, GENEL M, BEZMAN RJ, SLANETZ PJ:Diagnosis and treatment of attention-deficit hyperactivity disorder in children and adolescents. JAMA (1998) 279001100–1107.
   Google Scholar
• BIEDERMAN J, WILENS T, MICK E, SPENCER T, FARONE SV: Ph armacotherapy of attention-deficit/hyperac-tivity disorder reduces risk for substance use disorder. Pediatrics (1999) 104 (2):e20.
   PubMed Web of Science ®Google Scholar
• FARAONE SV, BIEDERMAN J, SPENCER T et al: Attention-deficit/hyperactivity disorder in adults: an overview. Biol. Psychiatry (2000) 48 (9):9–20.
   PubMedGoogle Scholar
• THAPAR A: Attention deficit hyperactivity disorder: unravelling the molecular genetics. Mol. Psychiatry (1998) 3:370–372.
   PubMedGoogle Scholar
• ELIA J, AMBROSINI PJ, RAPOPORT JL: Drug therapy: treatment of attention-deficit hyperactivity disorder. NEJM (1999) 340(10):780–788.
   PubMedGoogle Scholar
• ANONYMOUS: Diagnosis and treatment of attention-deficit hyperactivity disorder (ADHD). NIH Consensus Statement (1998) 1 6 (2):1–37.
   Google Scholar
• MTA CO-OPERATIVE GROUP: A I4-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry (1999) 56:1073–1086.
   PubMedGoogle Scholar
• BARKLEY RA: Attention Deficit Hyperactivity Disorder: A Handbook forDiagnosis and Treatment. The Guilford Press, New York, USA (1990).
   Google Scholar
• WILENS TE: Controlled trial of high doses of pemoline for adults with attention-deficit/hyperactivity disorder. J. Clin. Psychopharmacology (1 9 9 9) 19 (3):257–264.
   Google Scholar
• WILENS TE, BIEDERMAN J, SPENCER TJ: Pharmaco-therapy of attention-deficit hyperactivity disorder in adults. CNS Drugs (1998) 9(5):347–356.
   Google Scholar
• HUNT RD, ARNSTEN AFD, ASBELL MD: An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry (1995) 34:50–54.
   PubMed Web of Science ®Google Scholar
• SWANSON JM, CONNER DF, CANTWELL D: Combining methylphenidate and clonidine: ill-advised. J. Am. Acad. Child Adolesc. Psychiatry (1999) 38:617–619.
   Google Scholar
• WILENS TE, SPENSER TJ: Combining methylphenidate and clonidine: a clinically sound medication option. J Am. Acad. Child Adolesc. Psychiatry (1999) 38:614–616.
   PubMed Web of Science ®Google Scholar
• WILENS TE, BIEDERMAN J, SPENCER TJ: Pharmaco-therapy of attention-deficit hyperactivity disorder. Cur. Opin. CPNS Invest. Drugs (1999) 1(4):453–465.
   Google Scholar
• •One of several excellent overviews, the authors discuss the safety and efficacy of available and exploratory ADHD treatments. Contains useful references to clinical studies.
   Google Scholar
• PLISZKA SR, MCCRACKEN JT, MAAS JW: Catecholaminesin attention deficit hyperactivity disorder: current perspectives. J. Am. Acad. Child Adolesc. Psychiatry (1996) 35:264–272.
   PubMed Web of Science ®Google Scholar
• BIEDERMAN J, SPENSER T: Attention-deficit/hyperac-tivity/disorder (ADHD) as a noradrenergic disorder. Biol. Psychiatry (1999) 46:1234–1242.
   PubMed Web of Science ®Google Scholar
• SPENCER T, BIEDERMAN J, WILENS T, HARDING M, O'DONNELL D, GRIFFIN S: Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J. Amer. Acad. Child Adolesc. Psychiatry (1996) 35 (0409–432.
   PubMed Web of Science ®Google Scholar
• WILLIAMS M, BIEDERMAN J, LEVIN E et al.: Attention-deficit hyperactivity disorder: toward novel therapies. Proceedings of the American College of Neuropsychophar-macology (13 May 1999).
   Google Scholar
• NDA submission for OROS(R) methylphenidate announced by ALZA and Crescendo Pharmaceuticals once-daily treatment for attention deficit hyperac-tivity disorder designed to deliver medication for duration of school day. Invest. Drugs database 21 July, 2000 Current Drugs Ltd., UK. Reference report 333428.
   Google Scholar
• SWANSON JM, SUNOHARA GA, KENNEDY JL et al.: Association of the dopamine receptor at (DRD4) gene with a refined phenotype of attention deficit hyperac-tivity disorder (ADHD): a family-based approach. Mot. Psychiatry (1998) 3 (0 :38–41.
   PubMedGoogle Scholar
• BIEDERMAN J, BALDESSARINI RJ, WRIGHT V, KNEE D, HARMATZ JS, GOLDBLATT A: A double-blind placebo controlled study of desipramine in the treatment of ADD. II. J. Am. Acad. Child Adolesc. Psychiatry (1989) 28:903–911.
   PubMed Web of Science ®Google Scholar
• DONNELLY M, RAPOPORT JL, POTTER WZ et al.: Fenflu-ramine and dex tro amphetamine treatment of childhood hyperactivity. Clinical and biochemical findings. Arch. Gen. Psychiatry (1989) 46:205–212.
   PubMed Web of Science ®Google Scholar
• MENESES A: 5-HT system and cognition. Neurosc. Behav. Rev. (1999) 23:1111–1125.
   PubMed Web of Science ®Google Scholar
• PAUWELS P: 5-HT1B/D receptor antagonists. Gen. Pharmacol (1997) 29:293–303.
   PubMedGoogle Scholar
• CONNOR DF, BARKLEY RA, DAVIS HT: A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clin. Pediatrics (2000) 39:15–25.
   PubMed Web of Science ®Google Scholar
• CYR M, BROWN C: Current drug therapy recommenda-tions for the treatment of attention deficit hyperac-tivity disorder. Drugs (1998) 5 6 (2):215–223.
   Google Scholar
• COMINGS DE, GADE-ANDAVOLU R, GONZALEZ N, BLAKE H, WU S, MACMURPHY JP: Additive effect of 3 noradrenergic genes (ADRA2A, ADRA2C, DBH) on attention-deficit hyperactivity disorder and learning disabilities in Tourette syndrome subjects. Clin. Genetics (1999) 55(3):160–172.
   PubMedGoogle Scholar
• LEURS R, BLANDINA P, TEDFORD C, TIMMERMAN H: Therapeutic potentials of histamine H3 receptor agonists and antagonists. Trends Pharmacol. Sci. (1998) 19:177–183.
   PubMed Web of Science ®Google Scholar
• •A concise review of the therapeutic potential of H3 agonists and antagonists.
   Google Scholar
• Head start: Johnson & Johnson finds an elusive gene and r aces to exploit It. Wall StreetJournal (26 May, 2000).
   Google Scholar
• LEURS R, HOFFMANN M, WIELAND K, TIMMERMAN H: H3 receptor gene is cloned at last. Trends Pharmacol. Sci. (2000) 21:11–12.
   PubMedGoogle Scholar
• TOZER MJ, KALINDJIAN SB: Histamine H3 receptor antagonists. Exp. Opin. Ther. Patents (2000) 10 (7) :1045–1055.
   Web of Science ®Google Scholar
• •An exceptional review of novel H3 antagonists, highlighting the diversity of structure and potential utility of these compounds.
   Google Scholar
• UN N-H, MEYER MD: Recent developments in neuronal nicotinic acetylcholine receptor modulators. Exp. Opin. Ther. Patents (1998) 8 (10) :991–1015.
   Google Scholar
• NUTT D: Substance-P antagonists: a new treatment for depression? Lancet (1998) 352 (9141) :1644–1646.
   PubMedGoogle Scholar
• STRANG J, BEARN J, GOSSOP M: Lpfexidine for opiate detoxification: Review of recent randomised and open controlled trials. Am. J. On. Addictions (1999) 8 (4):337–348.
   PubMed Web of Science ®Google Scholar
• RIGGS PD, LEON SL, MIKULICH SK, POTTLE LC: An open trial of bupropion for ADHD in adolescents with substance use disorders and conduct disorder. j Am. Acad. Child Adolesc. Psychiatry (1998) 37 (12):1271–1278.
   PubMed Web of Science ®Google Scholar
• Venlafaxine. Clinical Trials Monitor (1996) 10:Abstract 19557.
   Google Scholar
• SPENCER T, BIERDERMAN J, WILENS T et al.: Effective-ness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am. J. Psychiatry (1998) 155(5):693–695.
   PubMed Web of Science ®Google Scholar